Founding of BioNotus

The name BioNotus was given to indicate ‘what is known’ (in Latin: notus) by bioanalysis. It all started with bioanalysis in Q2 2017. BioNotus’ founders Johan Van Daele and Pieter Annaert are best friends since their time (1989 onwards) as pharmacy students at KU Leuven. Until 2017 they both developed their unique career paths.

Johan rejuvenated his mother’s pharmacy and specialized in developing and improving innovative formulations prepared in the pharmacy. He also acquired the skills of entrepreneurship and marketing as partner in Carl&Johan.

Pieter followed a mixed path between academia and pharmaceutical industry and is currently Full professor and Chair of the KU Leuven Department of Pharmaceutical and Pharmacological Sciences.

The need to professionalize bioanalytical support and to offer adequate capacity to clinical researchers in academic hospitals was the initial trigger to found BioNotus. But above all, Johan and Pieter wanted to have fun and enjoy applying and disseminating their complementary skills and knowledge. They have the continued vision to help researchers in need of affordable bioanalytical capabilities with acceptable timelines. Offering fit-for-purpose solutions is BioNotus’ legacy.

BioNotus team

BioNotus is nowadays blessed with talented scientists in the fields of Bioanalysis, Pharmacometrics (PMX) and In vitro ADMET evaluation. The PMX pillar resulted from the customers requests following bioanalytical services, fulfilling the critical step of turning data into actionable insights. BioNotus now has PMX experience both with the classical top-down and more physiologically relevant bottom-up computational approaches. And from Pieter’s academic habitat, the decades of expertise in the field of in vitro testing of Absorption, Distribution, Metabolism, Excretion and Toxicity, has seamlessly integrated in BioNotus’ portfolio of capabilities.

Bart Lammens

Scientist Bioanalysis

Bart Lammens

Scientist Bioanalysis

Bart Lammens joined BioNotus from 1st October 2018. He studied Pharmaceutical Sciences, option Drug Development at the KU Leuven and graduated as a Pharmacist in 2015. Bart completed an additional master Industrial Pharmacy including an internship at UCB Pharma in Braine-l’Alleud and an education program between the KU Leuven, University of Antwerp, Ghent University and VUB. As an Industrial Pharmacist, Bart did additional research work at the KU Leuven Drug Delivery and Disposition lab. His research was focused on formulation development of fixed dose combinations. During his research project, he mainly used bead coating as a formulation development technique. He further applied various lab analytical techniques including solid state analysis (mDSC and PXRD), release tests in USP II and LC-UV.

Yeghig Armoudjian

Senior Scientist Bioanalysis

Yeghig Armoudjian

Senior Scientist Bioanalysis

Yeghig Armoudjian obtained his Master degree in Chemical technologies in Armenia. Since 2014, Yeghig ambitiously worked to develop and validate more than fourteen bioanalytical methods (in accordance with FDA and EMA guidelines), for the determination of pharmaceuticals in human plasma using UHPLC - MS/MS. These methods were applied to analyse clinical samples for pharmacokinetic and pharmacodynamic studies. Yeghig's chemistry background and his determined work in the laboratory resulted in faster and more robust sample preparation techniques. Yeghig gained extensive troubleshooting skills while working with Sciex TQ MS/MSs, as well as Agilent and Shimadzu UHPLCs: these highly sensitive instruments need abundant care, to ensure continuous system performance, while obtaining reliable data and safeguarding instrument longevity. While working in a regulated environment, Yeghig adhered to the principles of GLP in all his laboratory activities. Some of Yeghig's activities have been published in highly ranked scientific journals.

Qi Lin

Scientist Bioanalysis

Qi Lin

Scientist Bioanalysis

Qi Lin achieved her PhD in Pharmaceutical Sciences at KU Leuven in 2019. Her expertise in LC method development and validation devotes to solve challenges on separation in the LC analysis of complex pharmaceutical substances (i.e. biosynthesized antibiotics or structurally similar compounds) or complex mixtures (i.e. drug product, tablets, injections, etc.). She has previously worked as an external research member for European Directorate for the Quality of Medicines (EDQM) in 2015 – 2019, as part of the PhD job responsibilities. Three LC methods were successfully developed and validated for the individual analysis of spiramycin, tylosin and apramycin, to separate and detect the API and >30 structurally related impurities. Meanwhile, several unknown impurities of three antibiotics were also characterized using LC-MS/MS for the first time. These LC methods have been reviewing by EDQM in order to be enrolled as standards in the European Pharmacopoeia. Since 2014, she has also worked for projects outsourced by UZ Leuven and pharmaceutical manufacturers, containing the analysis of different pharmaceutical products (tablets, injection, suspension and infusion) and API (prostaglandin, papaverine, sufentanil, ropivacaine, chirocaine, lincomycin, vancomycin, polymyxin and tobramycin) including method development and validation, assay, European Pharmacopoeial test and stability study. More than 20 projects have been completed with a high quality to the satisfaction of customers.

Thomas Bouillon

Senior Pharmacometrician

Thomas Bouillon

Senior Pharmacometrician

Thomas Bouillon is both a physician (board certified anesthesiologist) and expert pharmacometrician. His major contributions to the field of anesthesia are a clinically relevant model of drug induced respiratory depression and the "Smart Pilot TM" display system, which visualizes drug interactions at the point of care and is implemented in high end Draeger anesthesia workstations. In 2007 he joined Modeling&Simulation at Novartis as a senior expert modeler, later associate director. In this position he introduced cumulative kill as standard metric into the Novartis malaria portfolio. In 2015 he left Novartis due to a value conflict in the KAE609/cipargamin program. From 2016-2019 he worked as Associate Professor Pharmacometrics (PMX) at the department of Pharmaceutical Sciences, KU Leuven, successfully building a Pharmacometrics Lab de novo. His team, supported by a fwo/tbm grant, developed open source software, aiming at making PMX knowledge accessible for physicians at the bedside at no cost (TDMore R-package, currently not publicly available). Having been denied tenure despite 2 positive evaluations by the responsible "beoordelingscommissie", he joined Bionotus 20191201 as senior pharmacometrician.

Pieter Annaert

CSO

Pieter Annaert

CSO

Pieter Annaert is Professor at the Drug Delivery and Disposition lab of the KU Leuven department of Pharmaceutical and Pharmacological Sciences. His research in the field of mechanistic pharmacokinetics focuses on hepatobiliary drug disposition, drug transporters, drug-induced hepatotoxicity, pediatric drug development and physiologically-based pharmacokinetic (PBPK) modelling. After graduation as a Pharmacist in 1994 (KU Leuven), Dr. Annaert obtained his PhD from the same university in 1998, and did a 2-year postdoctoral fellowship at the University of North Carolina at Chapel Hill. Subsequently, he held the positions of Scientist and Senior Scientist (2001-2005) at the Department of Preclinical Pharmacokinetics of Johnson & Johnson PRD. Prof. Annaert joined the KU Leuven Drug Delivery and Disposition lab in October 2005, where he is currently supervising a group of 7 PhD researchers and one postdoctoral fellow. In the past 10 years, he has (co)-supervised 13 PhD researchers. Prof. Annaert has co-authored 120 research articles and currently serves on the editorial boards of Drug Metabolism and Disposition and Journal of Pharmaceutical Sciences. For many years, Prof. Annaert has been teaching courses on pharmacokinetics, drug development and drug compounding. Bewteen 2014 and 2020, he was program director for the Bachelor and Master programs in Pharmaceutical Sciences at KU Leuven. Since 2020 he is the Chair of the KU Leuven Department of Pharmaceutical and Pharmacological Sciences.

Johan Van Daele

CEO

Johan Van Daele

CEO

Johan Van Daele got his master degree in pharmacy at Katholieke Universiteit Leuven (Belgium). He has more than 20 years experience in the field of pharmacy, research and development of drugs, food supplements and cosmetics. He developed a passion for really helping people and making the difference where he can, in his pharmacy as well as in a Congo based NGO where he acts as public health coach. He had the opportunity of experiencing entrepreneurship and management at C&J Laboratories, where he is also in charge of R&D. Johan is happily married with Ann, and they are blessed with 2 wonderful children: Hanne-Elisabeth and Simon-Elias.

BioNotus Milestones

Company presentation